Cigna is close to a $4.0 billion deal to sell its Medicare Advantage unit

January 03, 2024 11:07 AM PST | By Invezz

Cigna is close to a $4.0 billion deal to sell its Medicare Advantage unit — Image source: Invezz

Cigna-HCSG deal could be worth up to $4.0 billion

Anonymous sources told the Wall Street Journal on Wednesday that the two companies are in exclusive negotiations which could lead to a $3.0 billion to $4.0 billion deal.

Such an agreement, they added, will likely be announced in the coming days provided that discussions don’t fall apart. In December, Elevance Health Inc was also reported interested in buying Cigna’s Medicare Advantage business (find out more).

The news arrives about a month before Cigna Group is scheduled to report its financial results for the fourth quarter. Consensus is for it to earn $6.52 a share versus $4.96 per share a year ago.

Medicare isn’t a major revenue source for Cigna

Cigna had spent $3.8 billion on buying HealthSpring in 2011 to get into Medicate Advantage. It was first reported considering a sale of that business in November of 2023.

Note that Medicare Advantage unit contributed only 4.4% to the total revenue Cigna generated from external customers in 2022. Commercial and pharmacy benefits management divisions bring in most of its revenue.

In 2018, Cigna made a $52 billion acquisition of Express Scripts to further bolster its position in PBM.

Watch here: https://www.youtube.com/embed/mDT2kDfaQo4?feature=oembed

Both Cigna and Healthcare Services Group Inc are yet to officially comment on the Wall Street Journal report. $HCSG is also down slightly on Wednesday.

The post Cigna is close to a $4.0 billion deal to sell its Medicare Advantage unit appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.